Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Unknown unknown |
Therapy | Cytarabine + Onvansertib |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | not applicable |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | acute myeloid leukemia | not applicable | Cytarabine + Onvansertib | Phase I | Actionable | In a Phase Ib trial, Onvansertib (PCM-075) and low-dose Cytosar-U (cytarabine) combination therapy resulted in an overall response rate of 13% (2/15) in patients with relapsed or refractory acute myeloid leukemia, with 1 patient achieving a complete remission without hematologic recovery, and 25% (3/12) of the evaluable patients achieved a >=50% reduction of bone marrow blasts (PMID: 32998961; NCT03303339). | 32998961 |
PubMed Id | Reference Title | Details |
---|---|---|
(32998961) | A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. | Full reference... |